Arrowhead

Digital Ally Announces Multi-Year Agreement with the Kansas City Chiefs

Retrieved on: 
Monday, April 8, 2024
Organization, Noise, Digital, Partnership, Arrowhead Stadium, Darkness, Law enforcement, Motion, Wind, EVO, Dust, Ecosystem, Super Bowl, DGLY, Kansas City Chiefs, Arrowhead, Video game

Lenexa, Kansas, April 08, 2024 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (NASDAQ: DGLY) (the “Company”), a leading provider of video solutions which develops, manufactures, and markets advanced video recording products and other critical safety products for law enforcement, emergency management, fleet safety and event security, today announced the signing of a multi-year agreement with the Super Bowl Champion Kansas City Chiefs. The deployment includes 120 FirstVu PRO body cameras, two QuickVu 24-bay docking stations, as well as the utilization of Digital Ally’s EVO Web cloud platform.

Key Points: 
  • The deployment includes 120 FirstVu PRO body cameras, two QuickVu 24-bay docking stations, as well as the utilization of Digital Ally’s EVO Web cloud platform.
  • The continued partnership with Digital Ally underscores the commitment to employing cutting-edge technology to safeguard and enhance the safety and security of stadium staff and attendees during various events hosted at the facility.
  • As part of Digital Ally’s complete ecosystem of video solution products, the FirstVu PRO is compatible with the recently released QuickVu docking station.
  • Digital Ally’s QuickVu system provides a comprehensive and elegant solution for charging, reviewing and offloading video evidence to the cloud.

Brown & Brown, Inc. announces senior leadership team appointments

Retrieved on: 
Monday, April 1, 2024
Arrowhead, E&S, Insurance, Brown & Brown, Growth, Management

DAYTONA BEACH, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE:BRO) (the “Company”) has announced the appointment of David Putz and Niels Seebeck to the senior leadership team.

Key Points: 
  • DAYTONA BEACH, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE:BRO) (the “Company”) has announced the appointment of David Putz and Niels Seebeck to the senior leadership team.
  • I am excited to welcome David and Niels to our senior leadership team.
  • Before joining Brown & Brown in 2019, Putz spent nearly 25 years at Zurich Insurance North America, where he was a member of the global leadership team, overseeing alternative markets, including crop, programs, automotive and captives businesses.
  • Niels joined the team in 2015 and is responsible for the growth and oversight of numerous programs, including portfolio management, underwriting and operations.

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
Sunday, April 7, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Arrowhead, Principal, Urinary tract infection, JAMA Cardiology, Apolipoprotein C-III, Risk, Headache, Patient, Hypertriglyceridemia, Diarrhea, COVID-19, American College, APOC3, Pancreatitis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).
  • Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.
  • These data were presented in a late-breaking oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta and simultaneously published in the journal JAMA Cardiology .
  • Subjects treated with plozasiran also showed improvements in multiple atherogenic lipid and lipoprotein levels, including remnant cholesterol, HDL-cholesterol, and non-HDL cholesterol.

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

Retrieved on: 
Monday, March 25, 2024
Infectious Diseases, Diabetes, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Arrowhead, Diagnosis, PALISADE, Patient, Hypertriglyceridemia, EAP, Science, Microsoft Access, American College, Clinical trial, RNA interference, FCS, Therapy, Physician, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS) who meet certain program eligibility criteria.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS) who meet certain program eligibility criteria.
  • Arrowhead will also present new final Phase 2 clinical data from the double-blind portion of the SHASTA-2 study of plozasiran in a late-breaking oral presentation at the upcoming American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24), being held in Atlanta on April 6-8, 2024.
  • “Arrowhead is committed to supporting patients living with various lipid disorders and the physicians who treat them.
  • “Our Phase 3 PALISADE study of plozasiran in patients with FCS is nearing completion and we are further supporting the patient community by initiating an expanded access program for patients and physicians interested in receiving treatment with plozasiran outside of a clinical trial.

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Retrieved on: 
Friday, March 8, 2024
Pharmaceutical, Genetics, Health, Clinical Trials, Wheelchair, Myotonia, Cataract, DMPK, Wasting, Exercise, Arrowhead, Conference, DM1, RNA, Muscle weakness, Patient, CUG, Primate, MDA, RNA interference, Episcopal conference, Vaccine

Patients with DM1 have muscle weakness and wasting, myotonia, cataracts, and often develop cardiac conduction abnormalities.

Key Points: 
  • Patients with DM1 have muscle weakness and wasting, myotonia, cataracts, and often develop cardiac conduction abnormalities.
  • Pathogenesis of DM1 is driven by an expanded CUG trinucleotide repeat in the 3’-untranslated region of DMPK transcripts.
  • These abnormal transcripts cause mis-regulated splicing, known as spliceopathy, for certain messenger RNAs which are directly linked to the clinical manifestations of DM1.
  • Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

ARROWHEAD LUXURY CARS CELEBRATES THE SEASON OF GIVING

Retrieved on: 
Monday, February 12, 2024
Dignity, Risk, Transport, Season, Family, Volvo, Homelessness, Arrowhead, Toy

GLENDALE, Ariz., Feb. 12, 2024 /PRNewswire/ -- Local dealerships Arrowhead BMW, Volvo Cars Arrowhead, and Jaguar Land Rover Arrowhead celebrated the Season of Giving by joining together with the Homeless Engagement Lift Partnership (H.E.L.P.)

Key Points: 
  • GLENDALE, Ariz., Feb. 12, 2024 /PRNewswire/ -- Local dealerships Arrowhead BMW, Volvo Cars Arrowhead, and Jaguar Land Rover Arrowhead celebrated the Season of Giving by joining together with the Homeless Engagement Lift Partnership (H.E.L.P.)
  • with the toys they had collected at an event held at Arrowhead BMW and surprised a local family with the vehicle donation.
  • A premier Arizona luxury car dealer, Arrowhead Luxury Cars makes the car-buying process simple.
  • Arrowhead Luxury Cars is located at 19250 AZ-101 Loop, Glendale, AZ 85308.

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results

Retrieved on: 
Tuesday, February 6, 2024
Infectious Diseases, Diabetes, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, DSM-IV codes, CTA, Obesity, Retirement, Patient, PIN, Head, IgA nephropathy, Marketing, Idiopathic pulmonary fibrosis, RNA interference, GLP, ARO, Arrowhead, Identified, Webcast, Liver, Pharmacy, Toxicology, Completeness, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023.
  • The Company is hosting a conference call today, February 6, 2024, at 4:30 p.m.
  • A replay of the webcast will be available approximately two hours after the conclusion of the call.
  • Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

Jim Davis, Renowned Geologist and the Leading Authority on Copper Mountain, Joins Myriad's Technical Committee

Retrieved on: 
Thursday, January 18, 2024
Neutron, Arrowhead, Encore, COP28, Uranium, Senate, Myriad, UN, Mining, University, Qualified person (European Union), Union Pacific Railroad, MIT, Human body temperature, Gold, ISR, Congress, International Atomic Energy Agency, Nabarlek, SCI, News, National instrument, Uranium mining

Much of this work was led by Jim Davis, and we are delighted he is joining our Technical Committee.

Key Points: 
  • Much of this work was led by Jim Davis, and we are delighted he is joining our Technical Committee.
  • His first discovery as a young geologist was the Arrowhead Uranium Mine located at the centre of Copper Mountain (see Figure 1 above).
  • Mr. Davis subsequently led Union Pacific's extensive exploration at Copper Mountain, leading to the discovery of the Canning Deposit and several others in the district.
  • He was Chief Consulting Geologist for Neutron Energy (now part of enCore), a previous owner of part of Copper Mountain.

Aduro Clean Technologies Presents at CEM AlphaNorth Capital Event and Extends Engagement with Arrowhead Business and Investment Decisions

Retrieved on: 
Tuesday, January 16, 2024
ACT, Arrowhead, Investment decisions, Chemistry, CEM, Oil, Capital, Marketing

During the event, Aduro will conduct one-on-one meetings with interested investors and other stakeholders.

Key Points: 
  • During the event, Aduro will conduct one-on-one meetings with interested investors and other stakeholders.
  • The Company has also extended its engagement with Arrowhead Business and Investment Decisions, LLC (“Arrowhead”), originally announced on May 4, 2023 , regarding the provision of investor relations services to the Company.
  • The Company is pleased to be participating in the CEM AlphaNorth Capital Event and to have the opportunity to showcase its recent achievements and discuss future plans with investors.
  • The Company is also pleased to announce that it has extended its marketing and investor relations agreement with Arrowhead.